By Badrul Hisham Yahaya

The term “stem cell” often provokes two reactions. For some, it represents hope. For others, it signals hype.

Both reactions are understandable. The phrase has been used in legitimate medical contexts for decades, yet it has also been stretched far beyond available evidence. The result is confusion.

Let us begin with clarity.

Stem cells are foundational cells in the body. They can renew themselves and, under appropriate biological signals, develop into specialised cells that help repair damaged tissues. This is not speculative science. It is basic human biology.

More importantly, stem cell therapy is not new.

Bone marrow transplantation, routinely used to treat leukaemia and other blood disorders, is a stem cell treatment. For over half a century, it has enabled the rebuilding of blood and immune systems in critically ill patients. Skin regeneration in severe burn cases depends on the body’s stem cell populations. Corneal stem cell therapy has restored vision in selected patients.

These are not experimental miracles. They are established medical practice.

Why then does the public continue to associate stem cells primarily with dramatic promises?

Part of the answer lies in how the term entered popular discourse. Headlines often emphasised potential before evidence matured. Claims of reversing paralysis, curing chronic diseases, or slowing ageing captured imagination. Hope is powerful, especially when conventional medicine has reached its limits.

But scientific progress does not move at the speed of headlines. It advances through careful stages: laboratory discovery, preclinical validation, controlled clinical trials, and regulatory approval. This process exists not to delay innovation, but to protect patients.

Today, there are clinics around the world offering stem cell–labelled treatments for a wide range of conditions, sometimes without robust data or regulatory oversight. Not every therapy described as “stem cell” is supported by credible evidence. Distinguishing between validated treatment and unproven intervention is essential.

At the same time, it is equally important not to dismiss the field as exaggerated. Regenerative medicine is advancing in meaningful ways.

At the Pusat Kanser Tun Abdullah Ahmad Badawi (PKTAAB), Universiti Sains Malaysia, research teams are investigating stem cell biology in the context of cancer, lung injury, and tissue repair. Our work focuses on understanding how cells behave within damaged environments, how regenerative signals can be controlled, and how therapies can be translated safely into clinical settings.

For example, lung regeneration research examines how airway tissues respond after injury, infection, or chronic inflammation. Chronic obstructive pulmonary disease and post-infectious lung damage remain major healthcare burdens. Understanding the mechanisms of repair is a necessary step before any therapeutic strategy can be responsibly developed.

Similarly, studies on cancer stem cell behaviour aim to understand why certain tumours resist treatment. Regenerative medicine in oncology is not about growing more cells indiscriminately. It is about understanding cellular control — when to promote repair, and when to inhibit abnormal growth.

Many regenerative approaches are currently in active investigation globally. These include cell-based therapies for neurodegenerative conditions, cardiac tissue repair following myocardial infarction, and advanced organoid systems that model disease in the laboratory. These efforts are scientifically rigorous but remain in clinical trial phases.

Experimental does not mean fraudulent. It means not yet established as standard care.

Stem cells possess regenerative potential, but regeneration is not instant restoration. Outcomes depend on disease mechanism, timing, cell preparation, delivery strategy, and patient selection. Simply introducing cells into the body without understanding these variables is not advanced medicine.

In approved settings, patients may experience improved tissue repair, reduced inflammation, or slowed disease progression. They should not expect guaranteed cures or complete reversal of long-standing disease.

One misconception that requires correction is the belief that more stem cells automatically translate to better healing. Cell therapy is complex. Cells respond to their environment. They differentiate, migrate, signal, or die depending on context. Without precise control, intervention becomes unpredictable.

This is precisely why regulatory oversight, ethics committees, and carefully designed clinical trials are indispensable. Responsible regenerative medicine demands scientific discipline.

The field itself is also evolving beyond whole-cell transplantation. Increasing attention is being directed towards extracellular vesicles, cell-derived signalling molecules, biomaterials, and organoid technologies that allow us to model disease more accurately. These approaches may offer more controlled and targeted strategies for future therapy.

For Malaysia, regenerative medicine presents both opportunity and responsibility. Building national capability requires sustained investment in infrastructure, training, and translational pathways. Centres such as PKTAAB contribute by integrating laboratory science, clinical collaboration, and ethical oversight within a structured research environment. Progress is incremental, but it is grounded in evidence.

Stem cells are neither miracle cures nor medical scams by default. They are biological tools. Their impact depends entirely on how carefully they are studied, regulated, and applied.

Patients play a role as well. Asking whether a therapy is approved, whether it is part of a registered clinical trial, and what evidence supports it is not scepticism. It is informed decision-making.

Stem cell science is already embedded within modern medicine. Its most meaningful advances are often quiet rather than dramatic. When guided by data, ethics, and transparency, regenerative medicine can expand therapeutic options in ways that are practical and sustainable.

The future of this field will not be built on promises. It will be built on proof.

_{The author is the Deputy Director (Research & Networking) of Pusat Kanser Tun Abdullah Ahmad Badawi, Universiti Sains Malaysia (USM) and may be reached at badrul@usm.my}